Blueprint Medicines (BPMC) Reports Q2 Loss of $0.62/Share

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.62), versus ($0.86) reported last year. Revenue for the quarter came in at $41.44 million, versus $5.89 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• S&P 500 may pull back before midterms, but Citi says buy the dip